


**Table S1.** Characteristics of seven patients with simultaneous tocilizumab measurements in the blood and urine.

|   | Age (years) | Sex    | Dose (mg) | Route of administration | TCZ plasma concentration (mg/L) | TCZ urinary concentration (mg/L) | ACR (mg/mmol) | GFR (mL/mn/1.73m <sup>2</sup> ) |
|---|-------------|--------|-----------|-------------------------|---------------------------------|----------------------------------|---------------|---------------------------------|
| 1 | 41          | Male   | 162       | SC                      | 67.9                            | <1                               | /             | 31                              |
| 2 | 73          | Male   | 552       | IV                      | 37.5                            | <1                               | 10            | 39                              |
| 3 | 54          | Male   | 736       | IV                      | 40.5                            | <1                               | 41.8          | 36                              |
| 4 | 31          | Male   | 162       | SC                      | 75.8                            | <1                               | 67.5          | /                               |
| 5 | 61          | Female | 480       | IV                      | 36.2                            | <1                               | 31.5          | 35                              |
| 6 | 46          | Male   | 608       | IV                      | 35.9                            | <1                               | 343.9         | 25                              |
| 7 | 77          | Female | 162       | SC                      | 124                             | 2.9                              | 948.8         | 30                              |

IV: intravenous, SC: subcutaneous, TCZ: tocilizumab, ACR: urinary albumin-to-creatinine ratio, GFR: glomerular filtration rate



**Figure S1.** Temporal evolution of the urinary albumin-to-creatinine ratio (ACR) before tocilizumab administration (M0) and at M1, M2, M3 and M6 after tocilizumab administration. Each colored line represents one patient. Box plots represent the medians and 25<sup>th</sup>-75<sup>th</sup> percentile. The red dotted line represents the threshold value of macroalbuminuria (ACR = 30 mg/mmol). Friedman test,  $\chi^2 = 3.83$ ,  $p = 0.430$ .